{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:25:02Z","timestamp":1791645902485,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd008834.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000}}],"reference-count":686,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008834.pub4","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:40:20Z","timestamp":1646041220000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Antiplatelet agents for chronic kidney disease"],"prefix":"10.1002","volume":"2022","author":[{"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria M","family":"Saglimbene","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Ruospo","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Razavian","sequence":"additional","affiliation":[{"name":"Renal and Metabolic Division; The George Institute for Global Health; Newtown Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J","family":"Jardine","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre; Camperdown Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C","family":"Webster","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Centre for Transplant and Renal Research, Westmead Millennium Institute; The University of Sydney at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD008834.pub4-BIB0001|cit1","first-page":"B5","article-title":"Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]","volume":"28","author":"Goicoechea","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study)","volume":"32","author":"Goicoechea","year":"2018","journal-title":"Cardiovascular Drugs & Therapy"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD008834.pub4-BIB0003|cit3","first-page":"726","article-title":"Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]","volume":"28","author":"Goicoechea","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.plefa.2017.08.009","article-title":"Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients","volume":"125","author":"Goicoechea","year":"2017","journal-title":"Prostaglandins Leukotrienes & Essential Fatty Acids"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0971-4065.139490","article-title":"Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study","volume":"25","author":"Abacilar","year":"2015","journal-title":"Indian Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1561-5413(07)60005-2","article-title":"Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study","volume":"9","author":"Abdul-Rahman","year":"2007","journal-title":"Hong Kong Journal of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","article-title":"Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity","volume":"9","author":"Alexopoulos","year":"2011","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0008|cit8","first-page":"417","article-title":"Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]","volume":"32","author":"Xanthopoulou","year":"2011","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0009|cit9","first-page":"93","article-title":"A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection","volume":"2","author":"Anderson","year":"1974","journal-title":"Clinical Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF01468835","article-title":"Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study","volume":"52","author":"Andrassy","year":"1974","journal-title":"Klinische Wochenschrift"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"E599","DOI":"10.21037\/jtd.2016.05.43","article-title":"Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial","volume":"8","author":"Di Franco","year":"2016","journal-title":"Journal of Thoracic Disease"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ahj.2007.10.003","article-title":"Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design","volume":"155","author":"Myles","year":"2008","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJMoa1507688","article-title":"Stopping vs. continuing aspirin before coronary artery surgery","volume":"374","author":"Myles","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1606424","article-title":"Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]","volume":"376","author":"Myles","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtcvs.2018.08.114","article-title":"Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial","volume":"157","author":"Myles","year":"2019","journal-title":"Journal of Thoracic & Cardiovascular Surgery"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jtcvs.2018.09.113","article-title":"Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial","volume":"157","author":"Myles","year":"2019","journal-title":"Journal of Thoracic & Cardiovascular Surgery"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD008834.pub4-BIB0017|cit17","first-page":"4B","article-title":"Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]","volume":"26","author":"Fujita","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2369-15-153","article-title":"A multinational phase IIb\/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design","volume":"15","author":"Nakamoto","year":"2014","journal-title":"BMC Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1744-9987.12840","article-title":"Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results","volume":"24","author":"Nakamoto","year":"2020","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0272-6386(87)80145-2","article-title":"Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis","volume":"9","author":"Chan","year":"1987","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jamaneurol.2018.0247","article-title":"Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial","volume":"75","author":"Jing","year":"2018","journal-title":"JAMA Neurology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1161\/STROKEAHA.115.008685","article-title":"Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack","volume":"46","author":"Li","year":"2015","journal-title":"Stroke"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/STROKEAHA.116.012901","article-title":"High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial","volume":"47","author":"Li","year":"2016","journal-title":"Stroke"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/STROKEAHA.116.016463","article-title":"Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants","volume":"48","author":"Lin","year":"2017","journal-title":"Stroke"},{"issue":"13","key":"10.1002\/14651858.CD008834.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.0000000000001972","article-title":"Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e003038","DOI":"10.1161\/JAHA.115.003038","article-title":"Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack","volume":"5","author":"Li","year":"2016","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2147\/TCRM.S156694","article-title":"Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight","volume":"14","author":"Ma","year":"2018","journal-title":"Therapeutics & Clinical Risk Management"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1161\/STROKEAHA.117.019081","article-title":"Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events)","volume":"48","author":"Pan","year":"2017","journal-title":"Stroke"},{"issue":"20","key":"10.1002\/14651858.CD008834.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1212\/WNL.0000000000003941","article-title":"Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]","volume":"88","author":"Pan","year":"2017","journal-title":"Neurology"},{"issue":"15","key":"10.1002\/14651858.CD008834.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0000000000003200","article-title":"Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA","volume":"87","author":"Pan","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.0000000000003719","article-title":"Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA","volume":"88","author":"Pan","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1161\/STROKEAHA.118.022077","article-title":"Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack","volume":"49","author":"Wang","year":"2018","journal-title":"Stroke"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1212\/WNL.0000000000006118","article-title":"Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA","volume":"91","author":"Wang","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/svn-2016-000008","article-title":"Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial","volume":"1","author":"Wang","year":"2016","journal-title":"Stroke & Vascular Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/svn-2017-000088","article-title":"Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial","volume":"2","author":"Wangqin","year":"2017","journal-title":"Stroke & Vascular Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.114.014791","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes","volume":"132","author":"Wang","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.2016.8662","article-title":"Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack","volume":"316","author":"Wang","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41397-018-0018-4","article-title":"Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy","volume":"18","author":"Wu","year":"2018","journal-title":"Pharmacogenomics Journal"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1161\/STROKEAHA.116.014761","article-title":"Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events)","volume":"47","author":"Zhou","year":"2016","journal-title":"Stroke"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1161\/STROKEAHA.118.022126","article-title":"Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke","volume":"49","author":"Zhu","year":"2018","journal-title":"Stroke"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0042|cit42","first-page":"872","article-title":"beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circulation: Cardiovascular Quality & Outcomes"},{"issue":"23","key":"10.1002\/14651858.CD008834.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1161\/CIRCULATIONAHA.109.895342","article-title":"Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial","volume":"121","author":"Berger","year":"2010","journal-title":"Circulation"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0045|cit45","first-page":"401","article-title":"A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]","volume":"150","author":"Bhatt","year":"2005","journal-title":"American Heart Journal"},{"issue":"16","key":"10.1002\/14651858.CD008834.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","article-title":"Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial)","volume":"103","author":"Dasgupta","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD008834.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","article-title":"Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk","volume":"118","author":"Eikelboom","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehp037","article-title":"The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease","volume":"30","author":"Mak","year":"2009","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-150-6-200903170-00006","article-title":"Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]","volume":"150","author":"Steinhubl","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurheartj\/ehm274","article-title":"An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial","volume":"28","author":"Wang","year":"2007","journal-title":"European Heart Journal"},{"issue":"1-2","key":"10.1002\/14651858.CD008834.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1797.1998.tb00316.x","article-title":"A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy","volume":"4","author":"Cheng","year":"1998","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0053|cit53","unstructured":"Cheng IK Fang GX Wong MC Ji YL Yeung H A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 45"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0054|cit54","first-page":"194","article-title":"A study of aspirin and dipyridamole in slowing the progression of diabetic glomerulosclerosis [abstract]","volume":"31","author":"Christopher","year":"1987","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0055|cit55","unstructured":"Christopher TG Samels K A study of the treatment effect of aspirin and dipyridamole in diabetic glomerulosclerosis [abstract] 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK 1987 56"},{"issue":"20 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0056|cit56","first-page":"B134","article-title":"The effect of cilostazol on the antiplatelet efficacy of patients with moderate renal dysfunction: post-hoc analysis of CILON-T (Influence of cilostazol based triple antiplatelet therapy on ischemic complication after drug eluting stent implantation) trial [abstract no: TCT-495]","volume":"58","author":"Lee","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0057|cit57","first-page":"87","article-title":"Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease","volume":"11","author":"Lee","year":"2010","journal-title":"Trials [Electronic Resource]"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","article-title":"Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial","volume":"57","author":"Suh","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ahj.2008.09.011","article-title":"Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"157","author":"Aronow","year":"2009","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2005.03.073","article-title":"Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"46","author":"Beinart","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0062|cit62","first-page":"287","article-title":"Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial","volume":"19","author":"Brener","year":"2007","journal-title":"Journal of Invasive Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s10198-005-0323-0","article-title":"The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial","volume":"6","author":"Ringborg","year":"2005","journal-title":"European Journal of Health Economics"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0065|cit65","unstructured":"Creek R Ticlopidine. Patency of haemodialysis access sites Guildford Sanofi Winthrop. Internal report 1990"},{"issue":"17","key":"10.1002\/14651858.CD008834.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1161\/01.CIR.0000035924.70846.20","article-title":"Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective","volume":"106","author":"Berger","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1067\/mhj.2003.180","article-title":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?","volume":"145","author":"Gerschutz","year":"2003","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.hjr.0000220582.19516.a6","article-title":"Renal function and outcomes in acute coronary syndrome: impact of clopidogrel","volume":"14","author":"Keltai","year":"2007","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ahj.2005.01.044","article-title":"Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"150","author":"Lewis","year":"2005","journal-title":"American Heart Journal"},{"issue":"9281","key":"10.1002\/14651858.CD008834.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"issue":"24","key":"10.1002\/14651858.CD008834.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1053\/euhj.2000.2474","article-title":"The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease","volume":"21","author":"Mehta","year":"2000","journal-title":"European Heart Journal"},{"issue":"14","key":"10.1002\/14651858.CD008834.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0073|cit73","first-page":"494","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]","volume":"345","author":"Yusuf","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0074|cit74","first-page":"902","article-title":"Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin","volume":"4","author":"Dash","year":"2013","journal-title":"International Journal of Preventive Medicine"},{"issue":"Nov","key":"10.1002\/14651858.CD008834.pub4-BIB0075|cit75","first-page":"506A","article-title":"Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]","volume":"14","author":"Dember","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.299.18.2164","article-title":"Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial","volume":"299","author":"Dember","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1191\/1740774505cn118oa","article-title":"Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial","volume":"2","author":"Dember","year":"2005","journal-title":"Clinical Trials"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub4-BIB0078|cit78","first-page":"229A","article-title":"Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]","volume":"13","author":"Dember","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.ajkd.2011.11.036","article-title":"Association of factor V gene polymorphism with arteriovenous graft failure","volume":"59","author":"Allon","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Issue","key":"10.1002\/14651858.CD008834.pub4-BIB0080|cit80","first-page":"256A","article-title":"Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]","volume":"19","author":"Dixon","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD008834.pub4-BIB0081|cit81","first-page":"506A","article-title":"Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]","volume":"14","author":"Dixon","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1191\/1740774505cn110oa","article-title":"Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial","volume":"2","author":"Dixon","year":"2005","journal-title":"Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1681\/ASN.2010060582","article-title":"Use of aspirin associates with longer primary patency of hemodialysis grafts","volume":"22","author":"Dixon","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Issue","key":"10.1002\/14651858.CD008834.pub4-BIB0084|cit84","first-page":"232A","article-title":"Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D\/A) to prevent graft failure [abstract no: F-PO841]","volume":"10","author":"Dixon","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa0805840","article-title":"Effect of dipyridamole plus aspirin on hemodialysis graft patency","volume":"360","author":"Dixon","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jvs.2013.02.143","article-title":"Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]","volume":"57","author":"Farber","year":"2013","journal-title":"Journal of Vascular Surgery"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jvs.2015.06.132","article-title":"The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts","volume":"62","author":"Farber","year":"2015","journal-title":"Journal of Vascular Surgery"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5414\/CN108100","article-title":"Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft","volume":"81","author":"Nee","year":"2014","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/BF02549745","article-title":"The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients","volume":"22","author":"Dmoszynska-Giannopoulou","year":"1990","journal-title":"International Urology & Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0090|cit90","unstructured":"Dodd NJ Turney JH Weston MJ Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F] Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco 1980"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0091|cit91","first-page":"121","article-title":"Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy [abstract]","volume":"23","author":"Donadio","year":"1983","journal-title":"Kidney International"},{"issue":"22","key":"10.1002\/14651858.CD008834.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJM198405313102203","article-title":"Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy","volume":"310","author":"Anderson","year":"1984","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ahj.2013.05.019","article-title":"Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb\/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial","volume":"166","author":"Bagai","year":"2013","journal-title":"American Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0094|cit94","first-page":"657","article-title":"Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]","volume":"32","author":"De Ferrari","year":"2011","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.ijcard.2013.01.061","article-title":"The relationship between meteorological conditions and index acute coronary events in a global clinical trial","volume":"168","author":"Ezekowitz","year":"2013","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijcard.2017.01.007","article-title":"Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS","volume":"232","author":"Farhan","year":"2017","journal-title":"International Journal of Cardiology"},{"issue":"22 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0097|cit97","article-title":"Fasting glucose, NT-proBNP, treatment with glycoprotein IIB\/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]","volume":"128","author":"Farhan","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ahj.2005.03.029","article-title":"The early glycoprotein IIb\/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale","volume":"149","author":"Giugliano","year":"2005","journal-title":"American Heart Journal"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0100|cit100","first-page":"246","article-title":"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS","volume":"2","author":"Hess","year":"2013","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ahj.2013.07.014","article-title":"Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial","volume":"166","author":"Kaul","year":"2013","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ahj.2013.01.009","article-title":"Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy","volume":"165","author":"Klutstein","year":"2013","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.amjcard.2014.01.404","article-title":"Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial)","volume":"113","author":"Kunadian","year":"2014","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.ijcard.2012.06.053","article-title":"Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial","volume":"167","author":"Lopes","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ahj.2011.08.020","article-title":"Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function","volume":"162","author":"Melloni","year":"2011","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/CIRCULATIONAHA.111.071860","article-title":"Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes","volume":"126","author":"Piccini","year":"2012","journal-title":"Circulation"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0107|cit107","article-title":"Association between angiographic complications during percutaneous coronary intervention and clinical outcomes among patients with acute coronary syndrome: an early ACS angiographic substudy [abstract no: A10394]","volume":"124","author":"Pride","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0108|cit108","first-page":"927","article-title":"Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb\/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy","volume":"5","author":"Pride","year":"2012","journal-title":"Jacc: Cardiovascular Interventions"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCOUTCOMES.111.962332","article-title":"Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial","volume":"5","author":"Roe","year":"2012","journal-title":"Circulation. Cardiovascular Quality & Outcomes"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"A120.E1122","DOI":"10.1016\/S0735-1097(10)61123-0","article-title":"Sex differences in high-risk acute coronary syndromes: Insights from early-ACS [abstract]","volume":"55","author":"Tanguay","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"14 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"E1101","DOI":"10.1016\/S0735-1097(11)61101-7","article-title":"Association of hub and spoke practice patterns with coronary intervention and outcomes in non ST elevation acute coronary syndromes (NSTE ACS): Insights from the early glycoprotein IIb\/IIIa inhibition in NSTE ACS (early-ACS) trial [abstract]","volume":"57","author":"Toleva","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ccd.25590","article-title":"Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb\/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial","volume":"84","author":"Toleva","year":"2014","journal-title":"Catheterization & Cardiovascular Interventions"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"A47.E451","DOI":"10.1016\/S0735-1097(10)60452-4","article-title":"Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (early ACS) trial [abstract]","volume":"55","author":"Wang","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.110.958041","article-title":"Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb\/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial","volume":"123","author":"Wang","year":"2011","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0115|cit115","first-page":"180","article-title":"Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]","volume":"12","author":"Ell","year":"1982","journal-title":"Haemostasis"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0116|cit116","first-page":"21","article-title":"Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial","volume":"8 Suppl B","author":"Aguirre","year":"1996","journal-title":"Journal of Invasive Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1161\/01.CIR.91.12.2882","article-title":"Bleeding complications with the chimeric antibody to platelet glycoprotein IIb\/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators","volume":"91","author":"Aguirre","year":"1995","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0735-1097(98)00252-6","article-title":"Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group","volume":"32","author":"Berkowitz","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9149(97)00796-0","article-title":"Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial","volume":"81","author":"Blankenship","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/0002-9149(94)90474-X","article-title":"Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications","volume":"74","author":"Boehrer","year":"1994","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/eurheartj\/16.suppl_L.43","article-title":"An overview of the results of the EPIC trial","volume":"16 Suppl L","author":"Califf","year":"1995","journal-title":"European Heart Journal"},{"issue":"14","key":"10.1002\/14651858.CD008834.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0735-1097(97)00423-3","article-title":"Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb\/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications","volume":"31","author":"Khan","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0735-1097(96)00239-2","article-title":"Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications","volume":"28","author":"Lefkovits","year":"1996","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0002-9149(96)00128-2","article-title":"Effects of platelet glycoprotein IIb\/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators","volume":"77","author":"Lefkovits","year":"1996","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0735-1097(97)00110-1","article-title":"Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb\/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications","volume":"30","author":"Lincoff","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9149(97)00589-4","article-title":"Effect of platelet glycoprotein IIb\/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb\/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications","volume":"80","author":"Mak","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.94.4.629","article-title":"Economic assessment of platelet glycoprotein IIb\/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators","volume":"94","author":"Mark","year":"1996","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0002-9149(99)80616-X","article-title":"Effect of platelet glycoprotein IIb\/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial","volume":"75","author":"Moliterno","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0735-1097(98)00620-2","article-title":"The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb\/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications","volume":"33","author":"Narins","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/hj.1999.v137.92521","article-title":"Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators","volume":"137","author":"Thel","year":"1999","journal-title":"American Heart Journal"},{"issue":"8902","key":"10.1002\/14651858.CD008834.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(94)90007-8","article-title":"Randomised trial of coronary intervention with antibody against platelet IIb\/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators","volume":"343","author":"Topol","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","article-title":"Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb\/IIIa Inhibition for Prevention of Ischemic Complication","volume":"278","author":"Topol","year":"1997","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S0002-8703(98)70302-3","article-title":"Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications","volume":"135","author":"Hout","year":"1998","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0135|cit135","first-page":"D59","article-title":"Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications","volume":"19 Suppl D","author":"Hout","year":"1998","journal-title":"European Heart Journal"},{"issue":"24","key":"10.1002\/14651858.CD008834.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0002-9149(98)00238-0","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb\/IIIa Receptor Blockade","volume":"82","author":"Ghaffari","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.CIR.97.9.857","article-title":"Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators","volume":"97","author":"Kereiakes","year":"1998","journal-title":"Circulation"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1161\/01.CIR.97.19.1912","article-title":"Diabetes mellitus, glycoprotein IIb\/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators","volume":"97","author":"Kleiman","year":"1998","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/14651858.CD008834.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/01.CIR.102.24.2923","article-title":"Economic assessment of platelet glycoprotein IIb\/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb\/IIIa blockade","volume":"102","author":"Lincoff","year":"2000","journal-title":"Circulation"},{"issue":"15","key":"10.1002\/14651858.CD008834.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.99.15.1951","article-title":"Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb\/IIIa blockade with abciximab. One-year outcome in the EPILOG trial","volume":"99","author":"Lincoff","year":"1999","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/15246090050147718","article-title":"Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial","volume":"9","author":"Cho","year":"2000","journal-title":"Journal of Womens Health & Gender-Based Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0143|cit143","first-page":"805","article-title":"Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb\/IIIa Inhibitor for Stenting (EPISTENT) trial","volume":"2","author":"De Servi","year":"2001","journal-title":"Italian Heart Journal Supplement"},{"issue":"9122","key":"10.1002\/14651858.CD008834.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0002-9149(02)02653-X","article-title":"Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb\/IIIa Inhibition in Stenting Trial (EPISTENT)","volume":"90","author":"Islam","year":"2002","journal-title":"American Journal of Cardiology"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD008834.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1067\/mhj.2000.103743","article-title":"Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial","volume":"139","author":"Lincoff","year":"2000","journal-title":"American Heart Journal"},{"issue":"25","key":"10.1002\/14651858.CD008834.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1161\/01.CIR.100.25.2477","article-title":"Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb\/IIIa inhibitor for stenting trial) diabetic substudy","volume":"100","author":"Marso","year":"1999","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/01.CIR.103.10.1403","article-title":"Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting (EPISTENT) Trial","volume":"103","author":"Steinhubl","year":"2001","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.281.9.806","article-title":"Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting","volume":"281","author":"Steinhubl","year":"1999","journal-title":"JAMA"},{"issue":"9195","key":"10.1002\/14651858.CD008834.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(99)10018-7","article-title":"Outcomes at 1 year and economic implications of platelet glycoprotein IIb\/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]","volume":"354","author":"Topol","year":"1999","journal-title":"Lancet"},{"issue":"16","key":"10.1002\/14651858.CD008834.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1053\/euhj.2000.2543","article-title":"Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb\/IIIa Inhibitor For Stenting Trial","volume":"22","author":"Zwart-van Rijkom","year":"2001","journal-title":"European Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators","volume":"268","year":"1992","journal-title":"JAMA"},{"issue":"14","key":"10.1002\/14651858.CD008834.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jacc.2018.07.046","article-title":"Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial","volume":"72","author":"Baumgartner","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/1358863X18775594","article-title":"Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial","volume":"23","author":"Berger","year":"2018","journal-title":"Vascular Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacc.2019.11.057","article-title":"Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease","volume":"75","author":"Haine","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCULATIONAHA.119.039773","article-title":"Acute limb ischemia in peripheral artery disease","volume":"140","author":"Hess","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/1358863X19864172","article-title":"Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial","volume":"24","author":"Hopley","year":"2019","journal-title":"Vascular Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.116.025880","article-title":"Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease","volume":"135","author":"Jones","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1161\/STROKEAHA.118.023534","article-title":"Stroke in patients with peripheral artery disease","volume":"50","author":"Kolls","year":"2019","journal-title":"Stroke"},{"issue":"25","key":"10.1002\/14651858.CD008834.pub4-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.jacc.2018.09.078","article-title":"Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial","volume":"72","author":"Low Wang","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejvs.2017.11.006","article-title":"Outcomes of patients with critical limb ischaemia in the EUCLID trial","volume":"55","author":"Norgren","year":"2018","journal-title":"European Journal of Vascular & Endovascular Surgery"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamacardio.2018.4171","article-title":"Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial","volume":"4","author":"Olivier","year":"2019","journal-title":"JAMA Cardiology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD008834.pub4-BIB0164|cit164","first-page":"905A","article-title":"High rate of screening failure in the FAVOURED study [abstract no: PUB345]","volume":"20","author":"Badve","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-10-1","article-title":"Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study","volume":"10","author":"Irish","year":"2009","journal-title":"BMC Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008834.pub4-BIB0166|cit166","first-page":"47","article-title":"Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]","volume":"21","author":"Irish","year":"2016","journal-title":"Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0167|cit167","first-page":"A45","article-title":"High rate of screening failure in the FAVOURED study [abstract no: 169]","volume":"14","author":"Irish","year":"2009","journal-title":"Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008834.pub4-BIB0168|cit168","first-page":"19","article-title":"Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]","volume":"19","author":"Irish","year":"2014","journal-title":"Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008834.pub4-BIB0169|cit169","first-page":"35","article-title":"Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]","volume":"15","author":"Irish","year":"2010","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamainternmed.2016.8029","article-title":"Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial","volume":"177","author":"Irish","year":"2017","journal-title":"JAMA Internal Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD008834.pub4-BIB0171|cit171","first-page":"B2","article-title":"The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]","volume":"26","author":"Irish","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008834.pub4-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"iii65","DOI":"10.1093\/ndt\/gfx122.MO049","article-title":"Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]","volume":"32","author":"Viecelli","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008834.pub4-BIB0173|cit173","first-page":"56","article-title":"Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]","volume":"23","author":"Viecelli","year":"2018","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008834.pub4-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"iii335","DOI":"10.1093\/ndt\/gfx153.SP593","article-title":"Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]","volume":"32","author":"Viecelli","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"i227","DOI":"10.1093\/ndt\/gfy104.FP555","article-title":"Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]","volume":"33","author":"Viecelli","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008834.pub4-BIB0176|cit176","first-page":"115","article-title":"A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]","volume":"21","author":"Viecelli","year":"2016","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12882-015-0089-2","article-title":"The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications","volume":"16","author":"Viecelli","year":"2015","journal-title":"BMC Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008834.pub4-BIB0178|cit178","first-page":"12","article-title":"Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]","volume":"22","author":"Viecelli","year":"2017","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/nep.12573","article-title":"Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study","volume":"21","author":"Viecelli","year":"2016","journal-title":"Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/nep.12823","article-title":"Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study","volume":"22","author":"Viecelli","year":"2017","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"e0213274","DOI":"10.1371\/journal.pone.0213274","article-title":"Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial","volume":"14","author":"Viecelli","year":"2019","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1525-1594.1985.tb04349.x","article-title":"Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis","volume":"9","author":"Fiskerstrand","year":"1985","journal-title":"Artificial Organs"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0183|cit183","first-page":"48","article-title":"Use of defibrotide in renal transplantation in man","volume":"16 Suppl 1","author":"Bonomini","year":"1986","journal-title":"Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0184|cit184","first-page":"231","article-title":"Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study","volume":"4","author":"Frasc\u00e0","year":"1986","journal-title":"Life Support Systems"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0185|cit185","first-page":"968","article-title":"A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]","volume":"10","author":"Frasc\u00e0","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-199713040-00002","article-title":"Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis","volume":"13","author":"Frasc\u00e0","year":"1997","journal-title":"Clinical Drug Investigation"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oxfordjournals.ndt.a027280","article-title":"Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function","volume":"11","author":"Frasc\u00e0","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ndt\/18.3.539","article-title":"Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate","volume":"18","author":"Gaede","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub4-BIB0189|cit189","first-page":"128A","article-title":"Lack of impact of low-dose acetylsalisyic acid (ASA) on albuminuria in type 2 diabetic patients [abstract no: A0660]","volume":"10","author":"Gaede","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/0971-4065.53323","article-title":"Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients","volume":"19","author":"Ghorbani","year":"2009","journal-title":"Indian Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0191|cit191","first-page":"109","article-title":"Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial","volume":"2","author":"Ghorbani","year":"2013","journal-title":"Journal of Renal Injury Prevention"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2337\/diabetes.47.3.423","article-title":"Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients","volume":"47","author":"Giustina","year":"1998","journal-title":"Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12933-020-01153-x","article-title":"Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial","volume":"19","author":"Gao","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00392-019-01586-9","article-title":"Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial","volume":"109","author":"Tomaniak","year":"2020","journal-title":"Clinical Research in Cardiology"},{"issue":"10151","key":"10.1002\/14651858.CD008834.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40620-019-00607-0","article-title":"Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial","volume":"32","author":"Morales","year":"2019","journal-title":"Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5301\/jn.5000077","article-title":"Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial","volume":"25","author":"Goicoechea","year":"2012","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0198|cit198","unstructured":"Gonzalez MT Castelao AM Valles M Cruzado JM Mauri JM Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEi) [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 200"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00365598509180223","article-title":"Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis","volume":"19","author":"Gr\u00f6ntoft","year":"1985","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0200|cit200","unstructured":"Gr\u00f6ntoft K Larsson R Mulec H Weiss LG Dickinson JP Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 398"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/003655998750015458","article-title":"Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group","volume":"32","author":"Gr\u00f6ntoft","year":"1998","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0202|cit202","first-page":"41","article-title":"Effect of acetylsalicylic acid on renal function of Type 1 diabetic patients with microalbuminuria","volume":"7","author":"Guo","year":"1998","journal-title":"Diabetes und Stoffwechsel"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.2337\/diacare.23.12.1742","article-title":"Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria","volume":"23","author":"Hansen","year":"2000","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM197909133011103","article-title":"Prevention of thrombosis in patients on hemodialysis by low-dose aspirin","volume":"301","author":"Harter","year":"1979","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/0886022X.2012.734758","article-title":"Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease","volume":"35","author":"Hidaka","year":"2013","journal-title":"Renal Failure"},{"issue":"9118","key":"10.1002\/14651858.CD008834.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/08037059709062088","article-title":"The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability","volume":"6","author":"Hansson","year":"1997","journal-title":"Blood Pressure"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3109\/08037059409102281","article-title":"The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results","volume":"3","author":"Hansson","year":"1994","journal-title":"Blood Pressure"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0209|cit209","first-page":"S9","article-title":"The Hypertension Optimal Treatment study and the importance of lowering blood pressure","volume":"17","author":"Hansson","year":"1999","journal-title":"Journal of Hypertension - Supplement"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008834.pub4-BIB0210|cit210","first-page":"49","article-title":"Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]","volume":"15","author":"Jardine","year":"2010","journal-title":"Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","article-title":"Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial","volume":"56","author":"Jardine","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"12 Pt 1-2","key":"10.1002\/14651858.CD008834.pub4-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0895-7061(99)00123-5","article-title":"The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study","volume":"12","author":"Jones","year":"1999","journal-title":"American Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1365-2796.2003.01135.x","article-title":"Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension","volume":"253","author":"Jonsson","year":"2003","journal-title":"Journal of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/01.HYP.31.4.1014","article-title":"Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects","volume":"31","author":"Kjeldsen","year":"1998","journal-title":"Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00004872-200018050-00017","article-title":"Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment","volume":"18","author":"Kjeldsen","year":"2000","journal-title":"Journal of Hypertension"},{"issue":"1-2","key":"10.1002\/14651858.CD008834.pub4-BIB0216|cit216","first-page":"1","article-title":"The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age","volume":"123","author":"Kolloch","year":"1998","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3-4","key":"10.1002\/14651858.CD008834.pub4-BIB0217|cit217","first-page":"217","article-title":"Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group","volume":"21","author":"Leonetti","year":"1999","journal-title":"Clinical Hemorheology & Microcirculation"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/080370598437358","article-title":"Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment","volume":"7","author":"Lithell","year":"1998","journal-title":"Blood Pressure"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1097\/00004872-200110000-00008","article-title":"Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study","volume":"19","author":"Mancia","year":"2001","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V122218","article-title":"Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study","volume":"12","author":"Ruilope","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1097\/00004872-200111000-00023","article-title":"Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study","volume":"19","author":"Struijker-Boudier","year":"2001","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/08037059309077529","article-title":"The Hypertension Optimal Treatment Study (the HOT Study)","volume":"2","year":"1993","journal-title":"Blood Pressure"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00004872-199917070-00022","article-title":"Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study","volume":"17","author":"Waeber","year":"1999","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/00004872-200106000-00021","article-title":"Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group","volume":"19","author":"Zanchetti","year":"2001","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00004872-200104000-00020","article-title":"Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study","volume":"19","author":"Zanchetti","year":"2001","journal-title":"Journal of Hypertension"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0002-9149(01)01972-5","article-title":"Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial","volume":"88","author":"Blankenship","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD008834.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0002-8703(99)70026-8","article-title":"Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience","volume":"138","author":"Gilchrist","year":"1999","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0735-1097(98)00130-2","article-title":"Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis","volume":"31","author":"Mandak","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"issue":"9063","key":"10.1002\/14651858.CD008834.pub4-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0735-1097(98)00551-8","article-title":"Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II","volume":"33","author":"Tardiff","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0002-9149(99)00767-5","article-title":"Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis","volume":"85","author":"Thel","year":"2000","journal-title":"American Journal of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD008834.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.3760\/cma.j.issn.0366-6999.20131503","article-title":"Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy","volume":"126","author":"Jiao","year":"2013","journal-title":"Chinese Medical Journal"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1253\/circj.CJ-13-0307","article-title":"Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk","volume":"77","author":"Okada","year":"2013","journal-title":"Circulation Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"e0147635","DOI":"10.1371\/journal.pone.0147635","article-title":"Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study","volume":"11","author":"Okada","year":"2016","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"22 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0236|cit236","article-title":"Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]","volume":"128","author":"Okada","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/dc10-1615","article-title":"Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial","volume":"34","author":"Saito","year":"2011","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008834.pub4-BIB0238|cit238","first-page":"iii487","article-title":"Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]","volume":"3","author":"Ohtake","year":"2010","journal-title":"NDT Plus"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1744-9987.12051","article-title":"Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients","volume":"18","author":"Ohtake","year":"2014","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM197402072900604","article-title":"Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone","volume":"290","author":"Kaegi","year":"1974","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1161\/01.CIR.52.3.497","article-title":"The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis","volume":"52","author":"Kaegi","year":"1975","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000190330","article-title":"Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients","volume":"77","author":"Kamper","year":"1997","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0243|cit243","first-page":"311","article-title":"Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole","volume":"12","author":"Kauffmann","year":"1980","journal-title":"Transplantation Proceedings"},{"issue":"Oct","key":"10.1002\/14651858.CD008834.pub4-BIB0244|cit244","first-page":"386A","article-title":"Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]","volume":"15","author":"Chang","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/01.ASN.0000081661.10246.33","article-title":"Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis","volume":"14","author":"Kaufman","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub4-BIB0246|cit246","first-page":"291A","article-title":"Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]","volume":"12","author":"Kaufman","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/003655902753679454","article-title":"A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy","volume":"36","author":"Khajehdehi","year":"2002","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0049-3848(80)90390-4","article-title":"Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study","volume":"20","author":"Kobayashi","year":"1980","journal-title":"Thrombosis Research"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0249|cit249","first-page":"415","article-title":"Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy","volume":"121","author":"Kontessis","year":"1993","journal-title":"Journal of Laboratory & Clinical Medicine"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0250|cit250","first-page":"277","article-title":"Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]","volume":"8","author":"Kooistra","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/9.8.1115","article-title":"Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin","volume":"9","author":"Kooistra","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0252|cit252","unstructured":"Koyama A Narita M Tojo S Therapeutic effects of dipyridamole on primary glomerulonephritis [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 12"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/0003319714538804","article-title":"High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention","volume":"66","author":"Liang","year":"2015","journal-title":"Angiology"},{"issue":"1 II","key":"10.1002\/14651858.CD008834.pub4-BIB0254|cit254","first-page":"196","article-title":"Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis","volume":"22","author":"Michie","year":"1977","journal-title":"Current Therapeutic Research - Clinical & Experimental"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0255|cit255","unstructured":"Middleton DA Deichsel G The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole Boehringer Ingelheim. Internal report 1992"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/039139889301600504","article-title":"Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers","volume":"16","author":"Milutinovic","year":"1993","journal-title":"International Journal of Artificial Organs"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0257|cit257","first-page":"44","article-title":"Desaggregation therapy of acute glomerulonephritis","volume":"79","author":"Movchan","year":"2001","journal-title":"Klinicheskaia Meditsina"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"762","DOI":"10.5812\/numonthly.8733","article-title":"Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD","volume":"5","author":"Mozafar","year":"2013","journal-title":"Nephrourology Monthly"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"e58135","DOI":"10.5812\/numonthly.58135","article-title":"Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial","volume":"10","author":"Mozafar","year":"2018","journal-title":"Nephro-Urology Monthly"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000045963","article-title":"Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease","volume":"88","author":"Nakamura","year":"2001","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000049435","article-title":"Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients","volume":"25","author":"Nakamura","year":"2002","journal-title":"Kidney & Blood Pressure Research"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0262|cit262","unstructured":"Guo X A clinical study to evaluate the efficacy and safety of cilostazol and probucol in combination on patients with diabetic nephropathy www.clinicaltrials.gov\/show\/nct01252056"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0263|cit263","first-page":"184","article-title":"A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study","volume":"21","author":"Nyberg","year":"1984","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2215\/CJN.03450807","article-title":"Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes","volume":"3","author":"Ogawa","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"18 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"B200","DOI":"10.1016\/j.jacc.2017.09.1118","article-title":"Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]","volume":"70","author":"Han","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bcp.13436","article-title":"Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease","volume":"84","author":"Wang","year":"2018","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0267|cit267","first-page":"9","article-title":"Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) - A double-blind comparison with ticlopidine hydrochloride","volume":"24","author":"Ota","year":"1996","journal-title":"Rinsho Hyoka"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ahj.2013.12.020","article-title":"Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial","volume":"167","author":"Bonaca","year":"2014","journal-title":"American Heart Journal"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub4-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.116.024637","article-title":"Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)","volume":"134","author":"Bonaca","year":"2016","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0271|cit271","first-page":"794","article-title":"Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]","volume":"38","author":"Dellborg","year":"2017","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacc.2017.08.083","article-title":"Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups","volume":"71","author":"Lozano","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0273|cit273","first-page":"520","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]","volume":"36","author":"Magnani","year":"2015","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0274|cit274","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial","volume":"37","author":"Magnani","year":"2016","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jacc.2017.10.079","article-title":"Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups","volume":"71","author":"Magnuson","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.05.063","article-title":"Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial","volume":"70","author":"Magnuson","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008834.pub4-BIB0277|cit277","article-title":"Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]","volume":"132","author":"Murphy","year":"2015","journal-title":"Circulation"},{"issue":"20 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0278|cit278","first-page":"B135","article-title":"Objectives: The purpose of this study was to determine the functional impact of cilostazol in patients with chronic kidney disease (CKD) undergoing hemodialysis [abstract no: TCT-497]","volume":"58","author":"Kim","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"8 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjcard.2011.02.244","article-title":"A comparison of clopidogrel responsiveness in patients with chronic renal failure: results of the adjunctive cilostazol versus high maintenance dose clopidogrel (PIANO) study [abstract no: AS-252]","volume":"107","author":"Woo","year":"2011","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ahj.2011.09.003","article-title":"Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study","volume":"162","author":"Woo","year":"2011","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1053\/j.ajkd.2014.11.023","article-title":"Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study","volume":"65","author":"Jeong","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008834.pub4-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"iii276","DOI":"10.1093\/ndt\/gfv181.03","article-title":"Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]","volume":"30","author":"Jeong","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0283|cit283","first-page":"7","article-title":"Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]","volume":"35","author":"Woo","year":"2014","journal-title":"European Heart Journal"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD008834.pub4-BIB0284|cit284","first-page":"529A","article-title":"Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]","volume":"26","author":"Kim","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2017.03.026","article-title":"The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis","volume":"238","author":"Kim","year":"2017","journal-title":"International Journal of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0286|cit286","first-page":"636","article-title":"Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]","volume":"37","author":"Kim","year":"2016","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0287|cit287","first-page":"281","article-title":"Low dose aspirin in patients with lupus nephritis [abstract]","volume":"33","author":"Pierucci","year":"1988","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0288|cit288","first-page":"283","article-title":"Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis [abstract]","volume":"31","author":"Pierucci","year":"1987","journal-title":"Kidney International"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198902163200703","article-title":"Improvement of renal function with selective thromboxane antagonism in lupus nephritis","volume":"320","author":"Pierucci","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1373\/clinchem.2012.200709","article-title":"Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study","volume":"59","author":"Akerblom","year":"2013","journal-title":"Clinical Chemistry"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ahj.2012.08.017","article-title":"Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study","volume":"164","author":"Akerblom","year":"2012","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"e002490","DOI":"10.1161\/JAHA.115.002490","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"4","author":"Andell","year":"2015","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/CIRCULATIONAHA.111.047530","article-title":"ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy","volume":"125","author":"Armstrong","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.amjmed.2013.01.038","article-title":"Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy","volume":"126","author":"Armstrong","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"23","key":"10.1002\/14651858.CD008834.pub4-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]","volume":"32","author":"Becker","year":"2011","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"e000557","DOI":"10.1136\/openhrt-2016-000557","article-title":"Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial","volume":"4","author":"Bellavia","year":"2017","journal-title":"Open Heart"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ahj.2013.06.019","article-title":"Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial","volume":"166","author":"Brilakis","year":"2013","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0298|cit298","first-page":"e002951","article-title":"Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"9","author":"Bui","year":"2016","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2459\/JCM.0b013e32834f23bd","article-title":"Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment","volume":"13","author":"Capodanno","year":"2012","journal-title":"Journal of Cardiovascular Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ahj.2012.06.005","article-title":"Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"164","author":"Cornel","year":"2012","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jacc.2014.11.034","article-title":"Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study","volume":"65","author":"Cowper","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ijcard.2013.06.135","article-title":"Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial","volume":"168","author":"DiNicolantonio","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1016\/j.ijcard.2013.07.020","article-title":"Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial","volume":"168","author":"DiNicolantonio","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2013.08.085","article-title":"Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel","volume":"169","author":"DiNicolantonio","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4244\/EIJY14M09_11","article-title":"Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial","volume":"11","author":"Ducrocq","year":"2015","journal-title":"Eurointervention"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"e011139","DOI":"10.1161\/JAHA.118.011139","article-title":"Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial","volume":"8","author":"Franchi","year":"2019","journal-title":"Journal of the American Heart Association"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0307|cit307","first-page":"500","article-title":"Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy","volume":"6","author":"Giannitsis","year":"2017","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"issue":"16","key":"10.1002\/14651858.CD008834.pub4-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/eurheartj\/ehv491","article-title":"Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study","volume":"37","author":"Hagstrom","year":"2016","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.964395","article-title":"Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"5","author":"Husted","year":"2012","journal-title":"Circulation. Cardiovascular Quality & Outcomes"},{"issue":"23","key":"10.1002\/14651858.CD008834.pub4-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/eurheartj\/ehu075","article-title":"The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"35","author":"Husted","year":"2014","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"American Heart Journal"},{"issue":"24","key":"10.1002\/14651858.CD008834.pub4-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"d3527","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"342","author":"James","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/CIRCGENETICS.114.000724","article-title":"NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO)","volume":"8","author":"Johansson","year":"2015","journal-title":"Circulation. Cardiovascular Genetics"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ahj.2015.03.015","article-title":"Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"169","author":"Kang","year":"2015","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.amjmed.2015.03.005","article-title":"Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex","volume":"128","author":"Kholaif","year":"2015","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/CIRCULATIONAHA.112.124248","article-title":"Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study","volume":"127","author":"Kohli","year":"2013","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0321|cit321","first-page":"319","article-title":"Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]","volume":"35","author":"Kontny","year":"2014","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ahj.2014.04.001","article-title":"Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"168","author":"Kotsia","year":"2014","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0323|cit323","first-page":"671","article-title":"Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)","volume":"6","author":"Kunadian","year":"2013","journal-title":"Jacc: Cardiovascular Interventions"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jval.2013.01.013","article-title":"Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial","volume":"16","author":"Levin","year":"2013","journal-title":"Value in Health"},{"issue":"31","key":"10.1002\/14651858.CD008834.pub4-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/eurheartj\/ehu160","article-title":"Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial","volume":"35","author":"Lindholm","year":"2014","journal-title":"European Heart Journal"},{"issue":"15","key":"10.1002\/14651858.CD008834.pub4-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jacc.2014.01.038","article-title":"Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"63","author":"Mahaffey","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/eurheartj\/ehs149","article-title":"Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study","volume":"34","author":"Nikolic","year":"2013","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1160\/TH11-03-0159","article-title":"Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany \"Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified\" (Thromb Haemost 2011; 105.5)","volume":"105","author":"Ohman","year":"2011","journal-title":"Thrombosis & Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/09537104.2018.1478404","article-title":"Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study","volume":"30","author":"Parker","year":"2019","journal-title":"Platelets"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/2047487314533215","article-title":"Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial","volume":"22","author":"Patel","year":"2015","journal-title":"European Journal of Preventive Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/clc.22733","article-title":"Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial","volume":"40","author":"Davoudi","year":"2017","journal-title":"Clinical Cardiology"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub4-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1161\/CIRCULATIONAHA.113.006524","article-title":"Letter by Roguin and Musallam regarding article, \"Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial\"","volume":"129","author":"Roguin","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2018.04.020","article-title":"Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis","volume":"202","author":"Scirica","year":"2018","journal-title":"American Heart Journal"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub4-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2010.11.056","article-title":"The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy","volume":"57","author":"Scirica","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/j.amjmed.2016.12.037","article-title":"Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths","volume":"130","author":"Serebruany","year":"2017","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000357261","article-title":"Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies","volume":"127","author":"Serebruany","year":"2014","journal-title":"Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2013.12.025","article-title":"Discrepancies in the primary PLATO trial publication and the FDA reviews","volume":"172","author":"Serebruany","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MJT.0b013e318245ce6c","article-title":"Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review","volume":"19","author":"Serebruany","year":"2012","journal-title":"American Journal of Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000335476","article-title":"The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent","volume":"120","author":"Serebruany","year":"2011","journal-title":"Cardiology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2016.03.015","article-title":"Impact of glycoprotein IIb\/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"177","author":"Shimada","year":"2016","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1503\/cmaj.111683","article-title":"Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial","volume":"184","author":"Siha","year":"2012","journal-title":"CMAJ Canadian Medical Association Journal"},{"issue":"19","key":"10.1002\/14651858.CD008834.pub4-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1161\/CIRCULATIONAHA.114.009353","article-title":"Response to letter regarding article, \"Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial\"","volume":"129","author":"Steg","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/CIRCULATIONAHA.113.002589","article-title":"Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial","volume":"128","author":"Steg","year":"2013","journal-title":"Circulation"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub4-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","article-title":"Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis","volume":"122","author":"Steg","year":"2010","journal-title":"Circulation"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub4-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1160\/TH17-05-0355","article-title":"Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study","volume":"118","author":"Storey","year":"2018","journal-title":"Thrombosis & Haemostasis"},{"issue":"23","key":"10.1002\/14651858.CD008834.pub4-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes","volume":"32","author":"Storey","year":"2011","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.amjcard.2011.07.015","article-title":"Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy)","volume":"108","author":"Storey","year":"2011","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/09537104.2013.842965","article-title":"Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study","volume":"25","author":"Storey","year":"2014","journal-title":"Platelets"},{"issue":"13","key":"10.1002\/14651858.CD008834.pub4-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"e007009","DOI":"10.1161\/JAHA.117.007009","article-title":"Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"7","author":"Ueland","year":"2018","journal-title":"Journal of the American Heart Association"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0353|cit353","first-page":"486","article-title":"Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]","volume":"35","author":"Ueland","year":"2014","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijcard.2014.06.029","article-title":"No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014","volume":"176","author":"Wallentin","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.ijcard.2013.11.003","article-title":"Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013","volume":"170","author":"Wallentin","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0357|cit357","first-page":"760","article-title":"The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. \"Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified\" (Thromb Haemost 2011; 105.5)","volume":"105","author":"Wallentin","year":"2011","journal-title":"Thrombosis & Haemostasis"},{"issue":"9749","key":"10.1002\/14651858.CD008834.pub4-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.113.004420","article-title":"Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"129","author":"Wallentin","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc18-0078","article-title":"Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease","volume":"41","author":"Navarro-Gonzalez","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S0828-282X(09)70536-7","article-title":"Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study","volume":"25","author":"Huynh","journal-title":"Canadian Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2004.07.014","article-title":"Analysis of bleeding complications associated with glycoprotein IIb\/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study","volume":"100","author":"Huynh","year":"2005","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0002-8703(03)00255-2","article-title":"Effect of platelet glycoprotein IIb\/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina\/non-ST-elevation myocardial infarction (PRISM-PLUS Study)","volume":"146","author":"Huynh","year":"2003","journal-title":"American Heart Journal"},{"issue":"20","key":"10.1002\/14651858.CD008834.pub4-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/01.CIR.0000016359.94919.16","article-title":"Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial","volume":"105","author":"Snapinn","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ahj.2004.08.042","article-title":"Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial","volume":"149","author":"Mega","year":"2005","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.amjcard.2004.05.065","article-title":"Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)","volume":"94","author":"Morrow","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub4-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2003.12.021","article-title":"Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial","volume":"93","author":"Servoss","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD008834.pub4-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/euhj.1999.1526","article-title":"Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial","volume":"20","author":"Szucs","year":"1999","journal-title":"European Heart Journal"},{"issue":"20","key":"10.1002\/14651858.CD008834.pub4-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1161\/01.CIR.102.20.2466","article-title":"Glycoprotein IIb\/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina\/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study","volume":"102","author":"Theroux","year":"2000","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0002-9149(00)01386-2","article-title":"Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators","volume":"87","author":"Theroux","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"15","key":"10.1002\/14651858.CD008834.pub4-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/01.CIR.100.15.1609","article-title":"Intracoronary thrombus and platelet glycoprotein IIb\/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators","volume":"100","author":"Zhao","year":"1999","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/euhj.1999.1743","article-title":"Geographic variability in outcomes within an international trial of glycoprotein IIb\/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT","volume":"21","author":"Akkerhuis","year":"2000","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-0736(00)80069-2","article-title":"Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb\/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy","volume":"33","author":"Akkerhuis","year":"2000","journal-title":"Journal of Electrocardiology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0002-9149(99)00049-1","article-title":"Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb\/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy","volume":"83","author":"Alexander","year":"1999","journal-title":"American Journal of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD008834.pub4-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/01.CIR.101.22.2557","article-title":"Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators","volume":"101","author":"Boersma","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/euhj.2001.2711","article-title":"Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa\/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy","volume":"23","author":"Brown","year":"2002","journal-title":"European Heart Journal"},{"issue":"14","key":"10.1002\/14651858.CD008834.pub4-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/euhj.2001.3151","article-title":"Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial","volume":"23","author":"Chang","year":"2002","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0003-4975(00)01654-4","article-title":"Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy","volume":"70","author":"Dyke","year":"2000","journal-title":"Annals of Thoracic Surgery"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0735-1097(00)01143-8","article-title":"Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators","volume":"37","author":"Greenbaum","year":"2001","journal-title":"Journal of the American College of Cardiology"},{"issue":"4A","key":"10.1002\/14651858.CD008834.pub4-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0002-9149(97)00575-4","article-title":"Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy","volume":"80","author":"Harrington","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0002-8703(00)90089-9","article-title":"Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide. The PURSUIT trial investigators","volume":"139","author":"Hasdai","year":"2000","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/01.CIR.101.7.751","article-title":"Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators","volume":"101","author":"Kleiman","year":"2000","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0384|cit384","first-page":"773","article-title":"Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial","volume":"20","author":"Labinaz","year":"2004","journal-title":"Canadian Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/hc0302.102578","article-title":"Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial","volume":"105","author":"Labinaz","year":"2002","journal-title":"Circulation"},{"issue":"23","key":"10.1002\/14651858.CD008834.pub4-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1161\/hc4801.100358","article-title":"Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb\/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial","volume":"104","author":"Lauer","year":"2001","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1161\/01.CIR.102.10.1093","article-title":"Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb\/IIIa inhibition. Insights from the platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial","volume":"102","author":"Lincoff","year":"2000","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/CVM-2-4-180","article-title":"Systematic adjudication of myocardial infarction end-points in an international clinical trial","volume":"2","author":"Mahaffey","year":"2001","journal-title":"Current Controlled Trials in Cardiovascular Medicine"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub4-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/01.CIR.99.18.2371","article-title":"Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb\/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators","volume":"99","author":"Mahaffey","year":"1999","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.CIR.101.4.366","article-title":"Cost-effectiveness of platelet glycoprotein IIb\/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes","volume":"101","author":"Mark","year":"2000","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/14651858.CD008834.pub4-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1161\/01.CIR.102.24.2952","article-title":"Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators","volume":"102","author":"Marso","year":"2000","journal-title":"Circulation"},{"issue":"22","key":"10.1002\/14651858.CD008834.pub4-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1161\/01.CIR.99.22.2892","article-title":"Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience","volume":"99","author":"McClure","year":"1999","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0002-9149(00)01426-0","article-title":"Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy","volume":"87","author":"Peterson","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"PURSUIT Trial Investigators","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.CIR.102.10.1101","article-title":"Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators","volume":"102","author":"Roe","year":"2000","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/euhj.2001.2736","article-title":"Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb\/IIIa receptor blocker","volume":"23","author":"Ronner","year":"2002","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/S0735-1097(02)01897-1","article-title":"Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB\/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy","volume":"39","author":"Ronner","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0002-8703(03)00530-1","article-title":"Evaluating the benefits of glycoprotein IIb\/IIIa inhibitors in heart failure at baseline in acute coronary syndromes","volume":"147","author":"Srichai","year":"2004","journal-title":"American Heart Journal"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD008834.pub4-BIB0399|cit399","first-page":"969","article-title":"Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide","volume":"23","author":"Quarto Di Palo","year":"1991","journal-title":"Transplantation Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","article-title":"Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators","volume":"98","author":"Brener","year":"1998","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0002-9149(99)00421-X","article-title":"Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial","volume":"84","author":"Brener","year":"1999","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/08860228509104837","article-title":"Effects of dipyridamole on peritoneal clearances","volume":"9","author":"Reams","year":"1985","journal-title":"Uremia Investigation"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub4-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1161\/CIRCULATIONAHA.107.730259","article-title":"Embolic protection and platelet inhibition during renal artery stenting","volume":"117","author":"Cooper","year":"2008","journal-title":"Circulation"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0404|cit404","article-title":"Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]","volume":"126","author":"He","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ccd.22469","article-title":"Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy","volume":"76","author":"Kanjwal","year":"2010","journal-title":"Catheterization & Cardiovascular Interventions"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ccd.21932","article-title":"Complete versus partial distal embolic protection during renal artery stenting","volume":"73","author":"Kanjwal","year":"2009","journal-title":"Catheterization & Cardiovascular Interventions"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1161\/HYPERTENSIONAHA.110.155564","article-title":"Renal ischemia regulates marinobufagenin release in humans","volume":"56","author":"Tian","year":"2010","journal-title":"Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1358863X11419998","article-title":"Determinants of renal function in patients with renal artery stenosis","volume":"16","author":"Yu","year":"2011","journal-title":"Vascular Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0409|cit409","first-page":"451","article-title":"The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients","volume":"9","author":"Rouzrokh","year":"2010","journal-title":"Iranian Journal of Pharmaceutical Research"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ki.1982.226","article-title":"Augmentation of peritoneal clearance by dipyridamole","volume":"22","author":"Rubin","year":"1982","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0411|cit411","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1525-1594.1984.tb04244.x","article-title":"Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole","volume":"8","author":"Salter","year":"1984","journal-title":"Artificial Organs"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0412|cit412","unstructured":"Schnepp M Teichler S Markau S Rettkowski O Priesack J Deuber HJ Platelet function analysis during therapy with clopidogrel in endstage renal disease [abstract] 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17-20; Nice, France 2000 191"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0413|cit413","first-page":"255","article-title":"The effect of dipyridamole on the results of allogenic kidney transplantation","volume":"83","author":"Schulze","year":"1990","journal-title":"Zeitschrift f\u00fcr Urologie und Nephrologie"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub4-BIB0414|cit414","first-page":"388","article-title":"Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]","volume":"4","author":"Sreedhara","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/ki.1994.192","article-title":"Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study","volume":"45","author":"Sreedhara","year":"1994","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0416|cit416","first-page":"773","article-title":"Low dose anti-thromboxane reduces urinary albumin in patients with diabetic kidney disease [abstract no: SA-PO148]","volume":"29","author":"Steiness","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0417|cit417","first-page":"167","article-title":"A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients","volume":"8","author":"Mileti","year":"1995","journal-title":"Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0418|cit418","first-page":"312","article-title":"Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans","volume":"28","author":"Storck","year":"1996","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0419|cit419","first-page":"397","article-title":"Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]","volume":"3","author":"Taber","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-013-0002-3","article-title":"Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"45","author":"Tang","year":"2014","journal-title":"Endocrine"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ahj.2004.12.002","article-title":"The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb\/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial","volume":"149","author":"Berger","year":"2005","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0422|cit422","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ccd.20963","article-title":"Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?)","volume":"69","author":"Kalyanasundaram","year":"2007","journal-title":"Catheterization & Cardiovascular Interventions"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1067\/mhj.2000.110094","article-title":"A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study","volume":"140","author":"Moliterno","year":"2000","journal-title":"American Heart Journal"},{"issue":"9330","key":"10.1002\/14651858.CD008834.pub4-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(02)09605-8","article-title":"Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study","volume":"360","author":"Moliterno","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"10.1002\/14651858.CD008834.pub4-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/eurheartj\/ehi459","article-title":"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up","volume":"26","author":"Mukherjee","year":"2005","journal-title":"European Heart Journal"},{"issue":"23","key":"10.1002\/14651858.CD008834.pub4-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1161\/01.CIR.0000018123.02672.C7","article-title":"Impact of different platelet glycoprotein IIb\/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up","volume":"105","author":"Roffi","year":"2002","journal-title":"Circulation"},{"issue":"25","key":"10.1002\/14651858.CD008834.pub4-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0428|cit428","first-page":"6135","article-title":"Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial","volume":"10","author":"Tayebi","year":"2018","journal-title":"Electronic Physician [Electronic Resource]"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00228-018-2484-7","article-title":"Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function","volume":"74","author":"Teng","year":"2018","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11239-018-1779-y","article-title":"Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function","volume":"47","author":"Correa","year":"2019","journal-title":"Journal of Thrombosis & Thrombolysis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0431|cit431","article-title":"The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]","volume":"136","author":"Gaviria","year":"2017","journal-title":"Circulation"},{"issue":"15","key":"10.1002\/14651858.CD008834.pub4-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0433|cit433","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2009.06.027","article-title":"Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial","volume":"158","author":"Morrow","year":"2009","journal-title":"American Heart Journal"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0434|cit434","doi-asserted-by":"crossref","first-page":"E102","DOI":"10.1016\/S0735-1097(13)60103-5","article-title":"Effects of glycoprotein IIB\/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]","volume":"61","author":"Cornel","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0435|cit435","first-page":"687","article-title":"Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]","volume":"35","author":"Mahaffey","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0436|cit436","first-page":"1","article-title":"The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses","volume":"43 Suppl 2","author":"Abaci","year":"2015","journal-title":"Turk Kardiyoloji Dernegi Arsivi"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub4-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","article-title":"Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis","volume":"51","author":"Antman","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1161\/CIRCULATIONAHA.111.041160","article-title":"American College of Cardiology\/American Heart Association\/European Society of Cardiology\/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)","volume":"125","author":"Bonaca","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijcard.2010.10.054","article-title":"Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial","volume":"146","author":"Capodanno","year":"2011","journal-title":"International Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1161\/CIRCULATIONAHA.112.102509","article-title":"Letter by Damman et al regarding articles, \"Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)\" and \"American College of Cardiology\/American Heart Association\/European Society of Cardiology\/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)\"","volume":"126","author":"Damman","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0441|cit441","first-page":"363","article-title":"Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial","volume":"3","author":"De Servi","year":"2014","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jtcvs.2012.07.059","article-title":"Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis","volume":"145","author":"Goodnough","year":"2013","journal-title":"Journal of Thoracic & Cardiovascular Surgery"},{"issue":"23","key":"10.1002\/14651858.CD008834.pub4-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/CIRCULATIONAHA.110.002683","article-title":"Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38)","volume":"123","author":"Hochholzer","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2013.09.023","article-title":"Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38)","volume":"63","author":"Kohli","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.109.900704","article-title":"Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38","volume":"121","author":"Mahoney","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/14779072.7.1.17","article-title":"Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials","volume":"7","author":"Mariani","year":"2009","journal-title":"Expert Review of Cardiovascular Therapy"},{"issue":"9749","key":"10.1002\/14651858.CD008834.pub4-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD008834.pub4-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"Michelson","year":"2009","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1074248413497534","article-title":"Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial","volume":"18","author":"Mogabgab","year":"2013","journal-title":"Journal of Cardiovascular Pharmacology & Therapeutics"},{"issue":"9665","key":"10.1002\/14651858.CD008834.pub4-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD008834.pub4-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1093\/eurheartj\/ehn362","article-title":"Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial","volume":"29","author":"Murphy","year":"2008","journal-title":"European Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jacc.2009.05.025","article-title":"The efficacy and safety of prasugrel with and without a glycoprotein IIb\/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis","volume":"54","author":"O'Donoghue","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0453|cit453","first-page":"1275","article-title":"Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38)","volume":"6","author":"Ojeifo","year":"2013","journal-title":"Jacc: Cardiovascular Interventions"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0454|cit454","first-page":"63","article-title":"Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial","volume":"50","author":"Pakhomov","year":"2010","journal-title":"Kardiologiia"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0455|cit455","first-page":"306","article-title":"Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy","volume":"3","author":"Pride","year":"2010","journal-title":"Jacc: Cardiovascular Interventions"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0091270011406280","article-title":"Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy","volume":"52","author":"Riesmeyer","year":"2012","journal-title":"Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1161\/CIRCULATIONAHA.110.936757","article-title":"Letter by Serebruany regarding article, \"Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38\"","volume":"122","author":"Serebruany","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0458|cit458","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/j.1538-7836.2010.03923.x","article-title":"Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data","volume":"8","author":"Sorich","year":"2010","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0460|cit460","first-page":"604","article-title":"Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]","volume":"7","author":"Udell","year":"2014","journal-title":"Jacc: Cardiovascular Interventions"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0461|cit461","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1185\/03007995.2014.944638","article-title":"An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel","volume":"30","author":"Wilcox","year":"2014","journal-title":"Current Medical Research & Opinion"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","article-title":"Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)","volume":"152","author":"Wiviott","year":"2006","journal-title":"American Heart Journal"},{"issue":"9621","key":"10.1002\/14651858.CD008834.pub4-BIB0463|cit463","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(08)60422-5","article-title":"Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial","volume":"371","author":"Wiviott","year":"2008","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD008834.pub4-BIB0464|cit464","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0465|cit465","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.amjcard.2011.05.020","article-title":"Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies","volume":"108","author":"Wiviott","year":"2011","journal-title":"American Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0466|cit466","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/0091270009337942","article-title":"Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38","volume":"49","author":"Wrishko","year":"2009","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0467|cit467","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008834.pub4-BIB0468|cit468","first-page":"437A","article-title":"Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]","volume":"13","author":"Baigent","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0469|cit469","first-page":"A14237","article-title":"Effect of CYP2C19 genotype on inhibition of platelet aggregation in hemodialysis patients with coronary artery disease [abstract]","volume":"134","author":"Waseda","year":"2016","journal-title":"Circulation"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0470|cit470","article-title":"Long-term effects of sarpogrelate, a selective serotonin receptor antagonist, in diabetic patients with stable angina and chronic kidney disease [abstract no: 11204]","volume":"124","author":"Watanabe","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0471|cit471","first-page":"182","article-title":"The effect of dipyridamole (Di) on the peritoneal dialysis (PD) clearance of creatinine and urea - a double-blind study [abstract]","volume":"21","author":"Weseley","year":"1982","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0472|cit472","unstructured":"Xydakis D Papadagiannakis A Sfakianaki M Vakouti E Papachristoforou K The combination of clopidogrel (CL) and acetylsalicylic acid (ASA) inhibits more effective the platelet activation in haemodialysis patients with acute coronary syndromes (ACS) and high C reactive protein [abstract no: MP370] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 355"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008834.pub4-BIB0473|cit473","first-page":"S320","article-title":"The effects of different dose of clopidogrel in elderly patients with unstable angina combining chronic kidney disease [abstract no: P12]","volume":"64","author":"Yang","year":"2016","journal-title":"Journal of the American Geriatrics Society"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0474|cit474","first-page":"A86","article-title":"Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]","volume":"31","author":"Yuto","year":"2012","journal-title":"Kidney Research & Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0475|cit475","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ndt\/9.6.619","article-title":"Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial","volume":"9","author":"Z\u00e4uner","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0476|cit476","first-page":"580","article-title":"European Society of Cardiology: apixaban or aspirin in decreasing stroke risk (The AVERROES Trial) [abstract]","volume":"35","author":"Alexander","year":"2010","journal-title":"P and T"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1076029613507335","article-title":"Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on AVERROES trial","volume":"21","author":"Amin","year":"2015","journal-title":"Clinical & Applied Thrombosis\/Hemostasis"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1055\/s-0037-1613679","article-title":"Apixaban- calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial","volume":"1","author":"Bhagirath","year":"2017","journal-title":"TH Open"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"28","key":"10.1002\/14651858.CD008834.pub4-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/eurheartj\/ehu048","article-title":"Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial","volume":"35","author":"Coppens","year":"2014","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","article-title":"Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial","volume":"11","author":"Diener","year":"2012","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0482|cit482","first-page":"e81","article-title":"AVERROES: apixaban versus acetylsalicylic acid (ASA) to prevent strokes [abstract no: 127]","volume":"42","author":"Diener","year":"2011","journal-title":"Stroke"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0483|cit483","first-page":"465","article-title":"Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: A secondary analysis of the AVERROES trial [abstract]","volume":"32","author":"Eikelboom","year":"2011","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.05.007","article-title":"Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease","volume":"21","author":"Eikelboom","year":"2012","journal-title":"Journal of Stroke & Cerebrovascular Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0485|cit485","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ahj.2009.08.026","article-title":"Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment","volume":"159","author":"Eikelboom","year":"2010","journal-title":"American Heart Journal"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0486|cit486","doi-asserted-by":"crossref","first-page":"E572","DOI":"10.1016\/S0735-1097(12)60573-7","article-title":"Bleeding with aspirin and apixaban in patients unsuitable for vitamin K antagonist therapy: The AVERROES study [abstract]","volume":"59","author":"Flaker","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1161\/STROKEAHA.112.664144","article-title":"Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial","volume":"43","author":"Flaker","year":"2012","journal-title":"Stroke"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0488|cit488","first-page":"6","article-title":"Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): the AVERROES trial [abstract]","volume":"32","author":"Hart","year":"2011","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0489|cit489","first-page":"671","article-title":"Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial [abstract]","volume":"32","author":"Hohnloser","year":"2011","journal-title":"European Heart Journal"},{"issue":"35","key":"10.1002\/14651858.CD008834.pub4-BIB0490|cit490","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/eurheartj\/eht292","article-title":"The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial","volume":"34","author":"Hohnloser","year":"2013","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0491|cit491","first-page":"31","article-title":"Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study","volume":"6","author":"Lip","year":"2013","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0492|cit492","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1161\/STROKEAHA.114.005746","article-title":"Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study","volume":"45","author":"Lip","year":"2014","journal-title":"Stroke"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0493|cit493","article-title":"Impact of treatment with apixaban and aspirin in patients with atrial fibrillation in relation to the CHADS2 and CHA2DS2-vasc scores: the AVERROES study [abstract no: 15542]","volume":"124","author":"Lip","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/ageing\/afv156","article-title":"Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial","volume":"45","author":"Ng","year":"2016","journal-title":"Age & Ageing"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0495|cit495","first-page":"346","article-title":"Effect of combination therapy of captopril and dipyridamole on proteinuria in patients with IgA nephropathy [abstract]","volume":"5","author":"Bang","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0496|cit496","first-page":"1720","article-title":"Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy","volume":"10","author":"Caravaca","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0497|cit497","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12013-015-0580-1","article-title":"Tirofiban combined with fondaparinux for post-PCI treatment of patients with acute coronary syndrome and mild renal insufficiency","volume":"73","author":"Changjiang","year":"2015","journal-title":"Cell Biochemistry & Biophysics"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/112972980600700305","article-title":"Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis","volume":"7","author":"Coli","year":"2006","journal-title":"Journal of Vascular Access"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.amjcard.2008.12.017","article-title":"Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial)","volume":"103","author":"Brugts","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.amjcard.2008.06.035","article-title":"Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial)","volume":"102","author":"Mercado","year":"2008","journal-title":"American Journal of Cardiology"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub4-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","article-title":"Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events","volume":"342","author":"O'Neill","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0502|cit502","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/jrpp.JRPP_17_24","article-title":"Effect of pretreatment with omega-3 supplement on cardiac necrosis markers in chronic kidney disease patients undergoing elective percutaneous coronary intervention","volume":"6","author":"Foroughinia","year":"2017","journal-title":"Journal of Research in Pharmacy Practice"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"471","DOI":"10.15171\/apb.2018.055","article-title":"Impact of omega-3 supplementation on high sensitive C-reactive protein level and 30-day major adverse cardiac events after the implementation of coronary stent in patients with chronic kidney disease: a randomized clinical study","volume":"8","author":"Foroughinia","year":"2018","journal-title":"Advanced Pharmaceutical Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0504|cit504","first-page":"306","article-title":"Preventive treatment of patients after non-disabling cerebral ischaemia of presumed arterial origin: Comparative randomized study with intensive anticoagulant therapy or aspirin treatment","volume":"142","author":"Gorter","year":"1998","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0505|cit505","unstructured":"Lee G Choong HL Chian GSC Woo KT Stabilisation of elevated serum creatinine (CR) in dipyridamole (DYP) and warfarin (WAR) treated patients with IgA nephropathy (IGAN): a three year controlled trial [abstract] 9th Asian Colloquium in Nephrology; 1992 May 17-21; Seoul, Korea 1992 106"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0506|cit506","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1440-1797.1997.tb00201.x","article-title":"Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment","volume":"3","author":"Lee","year":"1997","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0507|cit507","first-page":"276","article-title":"Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment","volume":"31","author":"Lee","year":"1989","journal-title":"Clinical Nephrology"},{"issue":"7790","key":"10.1002\/14651858.CD008834.pub4-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(72)92656-6","article-title":"Reduction of thrombus formation on dialyser membranes by aspirin and RA 233","volume":"2","author":"Lindsay","year":"1972","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0509|cit509","first-page":"423","article-title":"Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER)","volume":"18","author":"Scarpioni","year":"2005","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0510|cit510","unstructured":"Scarpioni R Michieletti E Pavone L Gandolfi S Ricardi M Pecchini P Atherosclerotic renovascular disease (ARVD): medical therapy plus renal artery stenting (PTRS), compared with medical therapy alone, do not offer more chances in preventing cardio-vascular (CV) or renal events, preliminary results of a prospective, multicenter and randomized trial [abstract no: M074] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jvir.2018.03.003","article-title":"Interaction between albuminuria and treatment group outcomes for patients with renal artery stenosis: The NITER Study","volume":"29","author":"Siddiqui","year":"2018","journal-title":"Journal of Vascular & Interventional Radiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0512|cit512","first-page":"A16","article-title":"A randomised controlled trial of cardiovascular risk factor modification in end stage renal failure [abstract no: P62]","volume":"9","author":"Perkovic","year":"2004","journal-title":"Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD008834.pub4-BIB0513|cit513","first-page":"377","article-title":"A randomised controlled trial of cardiovascular risk factor modification in end stage kidney disease [abstract no: SA-PO348]","volume":"15","author":"Perkovic","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.mayocp.2012.12.014","article-title":"Protocol understanding and anxiety in perioperative clinical trial patients approached for consent on the day of surgery","volume":"88","author":"Chludzinski","year":"2013","journal-title":"Mayo Clinic Proceedings"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ahj.2014.01.007","article-title":"Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: an international 2 x 2 factorial randomized controlled trial of acetyl-salicylic acid vs. placebo and clonidine vs. placebo in patients undergoing noncardiac surgery","volume":"167","author":"Devereaux","year":"2014","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0516|cit516","doi-asserted-by":"crossref","first-page":"e004886","DOI":"10.1136\/bmjopen-2014-004886","article-title":"Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial","volume":"4","author":"Garg","year":"2014","journal-title":"BMJ Open"},{"issue":"21","key":"10.1002\/14651858.CD008834.pub4-BIB0517|cit517","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/jama.2014.15284","article-title":"Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial","volume":"312","author":"Garg","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0518|cit518","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijcard.2014.03.028","article-title":"Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy","volume":"173","author":"Campo","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0519|cit519","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jacc.2013.09.043","article-title":"Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)","volume":"63","author":"Campo","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0520|cit520","doi-asserted-by":"crossref","first-page":"e1222","DOI":"10.4244\/EIJY15M08_04","article-title":"Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration","volume":"11","author":"Costa","year":"2016","journal-title":"Eurointervention"},{"issue":"20","key":"10.1002\/14651858.CD008834.pub4-BIB0521|cit521","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/eurheartj\/ehv038","article-title":"Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial","volume":"36","author":"Costa","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0522|cit522","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2016.03.033","article-title":"Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial","volume":"212","author":"Crimi","year":"2016","journal-title":"International Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0523|cit523","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamacardio.2016.2811","article-title":"Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial","volume":"1","author":"Franzone","year":"2016","journal-title":"JAMA Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD008834.pub4-BIB0524|cit524","first-page":"1780","article-title":"Impact of sex on 2-year clinical outcomes in patients treated with 6-month or 24-month dual-antiplatelet therapy duration: a pre-specified analysis from the PRODIGY trial","volume":"9","author":"Gargiulo","year":"2016","journal-title":"Jacc: Cardiovascular Interventions"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0525|cit525","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ahj.2016.01.015","article-title":"Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial","volume":"174","author":"Gargiulo","year":"2016","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0526|cit526","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ccd.26921","article-title":"Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: an analysis from the PRODIGY trial","volume":"90","author":"Gargiulo","year":"2017","journal-title":"Catheterization & Cardiovascular Interventions"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0527|cit527","first-page":"104","article-title":"Impact of chronic kidney disease on two-year clinical outcomes in patients treated with a six-month or 24-month DAPT duration: insights from the PRODIGY trial [abstract]","author":"Santucci","year":"2016","journal-title":"Eurointervention"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0528|cit528","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"European Heart Journal"},{"issue":"16","key":"10.1002\/14651858.CD008834.pub4-BIB0529|cit529","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0530|cit530","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ahj.2010.07.034","article-title":"Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY)","volume":"160","author":"Valgimigli","year":"2010","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0531|cit531","first-page":"20","article-title":"Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY)","volume":"7","author":"Valgimigli","year":"2014","journal-title":"Jacc: Cardiovascular Interventions"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0532|cit532","first-page":"13","article-title":"Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial","volume":"22","author":"Marcantoni","year":"2009","journal-title":"Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0533|cit533","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.ajkd.2012.01.022","article-title":"Effect of renal artery stenting on left ventricular mass: a randomized clinical trial","volume":"60","author":"Marcantoni","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0534|cit534","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.amjcard.2005.12.050","article-title":"Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy)","volume":"97","author":"Blankenship","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0535|cit535","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ahj.2006.02.012","article-title":"Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial","volume":"151","author":"Chacko","year":"2006","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0536|cit536","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.amjcard.2004.11.003","article-title":"Bivalirudin versus heparin and glycoprotein IIb\/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)","volume":"95","author":"Chew","year":"2005","journal-title":"American Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0537|cit537","first-page":"1792","article-title":"Economic evaluation of bivalirudin with provisional glycoprotein IIB\/IIIA inhibition versus heparin with routine glycoprotein IIB\/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial","volume":"44","author":"Cohen","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0538|cit538","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2005.09.004","article-title":"Provisional glycoprotein IIb\/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb\/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial","volume":"152","author":"Exaire","year":"2006","journal-title":"American Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0539|cit539","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.amjcard.2007.06.026","article-title":"Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial","volume":"100","author":"Feit","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0540|cit540","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.amjcard.2007.01.053","article-title":"Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis)","volume":"99","author":"Gibson","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0541|cit541","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jacc.2005.02.074","article-title":"Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial","volume":"45","author":"Gurm","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0542|cit542","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.[Erratum in: JAMA. 2003 Apr 2;289(13):1638]","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0543|cit543","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","article-title":"Long-term efficacy of bivalirudin and provisional glycoprotein IIb\/IIIa blockade vs heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.[Erratum in: JAMA. 2006 Jul 5;296(1):46]","volume":"292","author":"Lincoff","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0544|cit544","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2004-831045","article-title":"Bivalirudin in PCI: an overview of the REPLACE-2 trial","volume":"30","author":"Maroo","year":"2004","journal-title":"Seminars in Thrombosis & Hemostasis"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0545|cit545","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ahj.2005.09.007","article-title":"Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial","volume":"152","author":"Rajagopal","year":"2006","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0546|cit546","first-page":"1194","article-title":"Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb\/IIIa blockade compared to heparin with routine glycoprotein IIb\/IIIa blockade: a REPLACE-2 substudy","volume":"44","author":"Saw","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"2-3","key":"10.1002\/14651858.CD008834.pub4-BIB0547|cit547","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0891-6632(91)90031-J","article-title":"Effect of urokinase on preservation of renal function in patients with diabetic nephropathy","volume":"5","author":"Sakai","year":"1991","journal-title":"Journal of Diabetic Complications"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0548|cit548","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2215\/CJN.00100117","article-title":"Post hoc analyses of randomized clinical trial for the effect of clopidogrel added to aspirin on kidney function","volume":"12","author":"Ikeme","year":"2017","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0549|cit549","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD008834.pub4-BIB0550|cit550","first-page":"43A","article-title":"Multifactorial intervention in patients with type 2 diabetes: long-term effects on mortality and vascular complications [abstract no: SA-FC042]","volume":"18","author":"Gaede","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0551|cit551","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2337\/dc07-2452","article-title":"Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study","volume":"31","author":"Gaede","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0552|cit552","unstructured":"Gaede P Vedel P Larsen N Jensen G Parving H Pedersen O The Steno-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181] 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1-5; Budapest, Hungary 2002"},{"issue":"September, Prog","key":"10.1002\/14651858.CD008834.pub4-BIB0553|cit553","first-page":"72A","article-title":"The STENO-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F-FC031]","volume":"13","author":"Gaede","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0554|cit554","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0555|cit555","first-page":"1357","article-title":"Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract no: A0561]","volume":"7","author":"Gaede","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0556|cit556","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/16.10.2028","article-title":"Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria","volume":"16","author":"Gaede","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9153","key":"10.1002\/14651858.CD008834.pub4-BIB0557|cit557","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"issue":"30","key":"10.1002\/14651858.CD008834.pub4-BIB0558|cit558","first-page":"4277","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study","volume":"161","author":"Gaede","year":"1999","journal-title":"Ugeskrift for Laeger"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.kint.2016.11.023","article-title":"Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.[Erratum in: Kidney Int. 2017 May;91(5):1257; PMID: 28407880]","volume":"91","author":"Oellgaard","year":"2017","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0560|cit560","first-page":"451","article-title":"Pharmacologic profile of diaspirin crosslinked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract no: 84P]","volume":"5","author":"Halstenson","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0561|cit561","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/0272-6386(95)90056-X","article-title":"Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients","volume":"26","author":"Swan","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0562|cit562","doi-asserted-by":"crossref","unstructured":"Swan SK Halstenson CE Collins AJ Ellefson J Parr K Blue J Pharmacodynamic and pharmacokinetic parameters of diaspirin cross-linked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 559","DOI":"10.1016\/0272-6386(95)90056-X"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0563|cit563","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehu262","article-title":"Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial","volume":"36","author":"Bakal","year":"2015","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0564|cit564","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/STROKEAHA.115.012454","article-title":"Time-varying effects of prasugrel versus clopidogrel on the long-term risks of stroke after acute coronary syndromes: results from the TRILOGY ACS trial","volume":"47","author":"Chin","year":"2016","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0565|cit565","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ahj.2010.04.022","article-title":"Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina\/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial","volume":"160","author":"Chin","year":"2010","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0566|cit566","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ahj.2014.04.011","article-title":"Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial.[Erratum in: Am Heart J. 2014 Oct;168(4):605]","volume":"168","author":"Cornel","year":"2014","journal-title":"American Heart Journal"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD008834.pub4-BIB0567|cit567","doi-asserted-by":"crossref","first-page":"E102","DOI":"10.1016\/S0735-1097(13)60103-5","article-title":"Effects of glycoprotein IIB\/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: Insights from the TRACER trial [abstract]","volume":"61","author":"Cornel","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD008834.pub4-BIB0568|cit568","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy","volume":"308","author":"Gurbel","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0569|cit569","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/clc.22533","article-title":"Association between very low levels of high-density lipoprotein cholesterol and long-term outcomes of patients with acute coronary syndrome treated without revascularization: insights from the TRILOGY ACS trial","volume":"39","author":"Hagstrom","year":"2016","journal-title":"Clinical Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0570|cit570","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.amjcard.2018.06.052","article-title":"Outcomes of patients receiving downstream revascularization after initial medical management for non-st-segment elevation acute coronary syndromes (from the TRILOGY ACS trial)","volume":"122","author":"Hinohara","year":"2018","journal-title":"American Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0571|cit571","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/clc.22562","article-title":"Dual antiplatelet therapy and outcomes in patients with atrial fibrillation and acute coronary syndromes managed medically without revascularization: insights from the TRILOGY ACS trial","volume":"39","author":"Piccini","year":"2016","journal-title":"Clinical Cardiology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0572|cit572","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ahj.2016.03.017","article-title":"Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial","volume":"178","author":"Kaul","year":"2016","journal-title":"American Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jacc.2016.01.034","article-title":"Spontaneous MI after non-st-segment elevation acute coronary syndrome managed without revascularization: the TRILOGY ACS trial","volume":"67","author":"Lopes","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0574|cit574","first-page":"443","article-title":"Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial","volume":"5","author":"Melloni","year":"2016","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0575|cit575","first-page":"231","article-title":"Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial","volume":"5","author":"White","year":"2016","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"issue":"9892","key":"10.1002\/14651858.CD008834.pub4-BIB0576|cit576","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(13)61451-8","article-title":"Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.[Erratum in: Lancet. 2013 Aug 31;382(9894):768]","volume":"382","author":"Wiviott","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MCA.0000000000000623","article-title":"Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial","volume":"29","author":"Yan","year":"2018","journal-title":"Coronary Artery Disease"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0578|cit578","first-page":"304","article-title":"Follow-up renal biopsies in IgA nephritic patients on triple therapy","volume":"28","author":"Woo","year":"1987","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0579|cit579","first-page":"226","article-title":"Controlled therapeutic trial of IgA nephritis with follow-up renal biopsies","volume":"17","author":"Woo","year":"1988","journal-title":"Annals of the Academy of Medicine, Singapore"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0580|cit580","first-page":"56","article-title":"Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis","volume":"27","author":"Woo","year":"1987","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0581|cit581","first-page":"60","article-title":"Effects of triple therapy in IgA nephritis: a follow-up study 5 years later","volume":"36","author":"Woo","year":"1991","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0582|cit582","unstructured":"Woo KT Lee GSL Lau YK Chiang GSC Lim CH Anti platelet therapy in IgA nephritis [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 13"},{"issue":"7","key":"10.1002\/14651858.CD008834.pub4-BIB0583|cit583","first-page":"2175","article-title":"Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate","volume":"10","author":"Wu","year":"2018","journal-title":"American Journal of Translational Research"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0584|cit584","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3109\/0886022X.2014.899880","article-title":"Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4\/H antibody-positive patients","volume":"36","author":"Yang","year":"2014","journal-title":"Renal Failure"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0585|cit585","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5301\/jva.5000660","article-title":"Initiation of antiplatelet medication after surgical thrombectomy jeopardized arteriovenous graft longevity","volume":"18","author":"Yeh","year":"2017","journal-title":"Journal of Vascular Access"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0586|cit586","first-page":"C208","article-title":"Prospective multicenter controlled therapeutic trial in IgA nephropathy in Japanese children: a preliminary report [abstract no: S-I-2]","volume":"6","author":"Ito","year":"1992","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0587|cit587","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"Kamei","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0588|cit588","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1681\/ASN.V101101","article-title":"A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group","volume":"10","author":"Yoshikawa","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0589|cit589","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/14.5.1097","article-title":"Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy - is it relevant for adult patients?","volume":"14","author":"Yoshikawa","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0590|cit590","first-page":"C31","article-title":"Corticosteroids and immunosuppressive drugs [abstract no: S8.2]","volume":"16","author":"Yoshikawa","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0591|cit591","first-page":"1401","article-title":"A controlled trial of prednisolone (P), azathioprine (A), heparin-warfarin (H-W) and dipyridamole (D) in newly diagnosed severe childhood IgA nephropathy (IGAN) [abstract no: A0779]","volume":"7","author":"Yoshikawa","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0592|cit592","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.transproceed.2009.04.006","article-title":"Relationship between platelet activation and acute rejection after renal transplantation","volume":"41","author":"Zhang","year":"2009","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0593|cit593","first-page":"507","article-title":"The efficacy and complications of aspirin versus heparin in postoperative prophylaxis against thrombosis in newly placed hemodialysis access [abstract no: 195]","volume":"6","author":"Zibari","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/0002-9343(83)90864-1","article-title":"Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis","volume":"75","author":"Zimmerman","year":"1983","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0595|cit595","unstructured":"Kim BK A randomized comparison of CLOpidogrel monotherapy versus extended dual-antiplatelet therapy beyond 12 months after implantation of drug-eluting StEnts in high-risk lesions or patients; A-CLOSE trial www.cris.nih.go.kr\/cris\/search\/detailSearch.do\/18621"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0596|cit596","unstructured":"Alexopoulos D A randomized, pharmacodynamic comparison of low dose ticagrelor to clopidogrel in patients with prior myocardial infarction (ALTIC) www.clinicaltrials.gov\/show\/nct02663713"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0597|cit597","unstructured":"Alexopoulos D Low dose ticagrelor versus low dose prasugrel in patients with prior myocardial infarction (ALTIC-2) www.clinicaltrials.gov\/show\/nct03387826"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0598|cit598","unstructured":"A randomized, pharmacodynamic comparison of ticagrelor 60mg bid vs prasugrel 5mg in patients with prior myocardial infarction www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004959-80\/GR"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0599|cit599","unstructured":"Gallagher H Roderick P Aspirin to target arterial events in chronic kidney disease (ATTACK) protocol final version 1.1 www.njl-admin.nihr.ac.uk\/document\/download\/2035436 2018"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0600|cit600","unstructured":"Zhao J Antiplatelet therapy for prevention of atherosclerosis in chronic kidney disease: a perspective, multi-center randomized controlled trial www.chictr.org.cn\/showproj.aspx?proj=34865"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0601|cit601","unstructured":"Evaluation the effect of clopidogrel in prevention of access graft thrombosis in upper extrimity in patients undergoing hemodialysis in Emam Reza's Hospital - Kermanshah,2012-2013 www.en.irct.ir\/trial\/12352"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0602|cit602","unstructured":"Study of aspirin effects on Permcath function in dialysis patients www.en.irct.ir\/trial\/13944"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0603|cit603","unstructured":"The effect of Cilostazol on the mean time of arteriovenous fistula maturation and its comparison to control group in patients with chronic renal failure referring to Emam Reza hospital of Mashhad University of Medical Sciences www.en.irct.ir\/trial\/27466"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0604|cit604","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ahj.2017.04.005","article-title":"Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design","volume":"189","author":"Violi","year":"2017","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0605|cit605","doi-asserted-by":"crossref","first-page":"e10516","DOI":"10.2196\/10516","article-title":"The use of aspirin to reduce the risk of thrombotic events in patients with end-stage renal disease: protocol for a randomized controlled trial","volume":"7","author":"Lemos Cerqueira","year":"2018","journal-title":"JMIR Research Protocols"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0606|cit606","unstructured":"Tong PC The use of cilostazol in patients with diabetic nephropathy www.clinicaltrials.gov\/show\/nct00272831"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0607|cit607","unstructured":"Tarng DC Aspirin in the prevention of cardiovascular events in hemodialysis patients www.clinicaltrials.gov\/ct2\/show\/NCT01198379"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0608|cit608","unstructured":"Bougatsa VF Ramipril and clopidogrel in oxidative stress, vascular inflammation and endothelial dysfunction in type 2 diabetes and diabetic nephropathy www.clinicaltrials.gov\/show\/nct01743014"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0609|cit609","unstructured":"Kim W Woo JS Genotype and platelet reactivity in patients on hemodialysis www.clinicaltrials.gov\/show\/nct02394145"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0610|cit610","unstructured":"Liu PY Platelet resistance with ticagrelor or standard-dose clopidogrel among CKD and ACS patients (APPROVE-SCKD) www.clinicaltrials.gov\/show\/nct02459288"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0611|cit611","unstructured":"Nicolau JC Platelet aggregation in patients with coronary artery disease and kidney dysfunction taking clopidogrel or ticagrelor www.clinicaltrials.gov\/show\/nct03039205"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0612|cit612","unstructured":"Banerjee S Baskar A Study comparing treatment effectiveness of guideline indicated APT for ACS in patients with CKD (CPRS-SKD) www.clinicaltrials.gov\/show\/nct03150667"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0613|cit613","unstructured":"Nishank J Chronic kidney disease (CKD) platelet study www.clinicaltrials.gov\/show\/nct03649711"},{"issue":"40","key":"10.1002\/14651858.CD008834.pub4-BIB0614|cit614","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3346\/jkms.2019.34.e261","article-title":"The prevention of contrast induced nephropathy by sarpogrelate: a prospective randomized controlled clinical trial","volume":"34","author":"Ki","year":"2019","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0615|cit615","first-page":"122","article-title":"The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial","volume":"11","author":"Park","year":"2010","journal-title":"Trials [Electronic Resource]"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0616|cit616","unstructured":"PRASTRO-III: a double-blind study of CS-747S versus clopidogrel sulfate in patients with thrombotic stroke having risk factors for stroke recurrence www.clinicaltrials.jp\/cti-user\/trial\/ShowDirect jsp?japicId=JapicCTI-184141"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0617|cit617","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cct.2015.04.005","article-title":"Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study","volume":"43","author":"Lee","year":"2015","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0618|cit618","unstructured":"Choi DS Effect of sarpogrelate on the nephropathy in type 2 diabetes (SONATA study) www.clinicaltrials.gov\/show\/NCT01869881"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0619|cit619","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ahj.2020.04.013","article-title":"TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial","volume":"225","author":"Laine","year":"2020","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0620|cit620","unstructured":"Pandit N Parakh N Gupta S TWILIGHT Study The anti platelet therapy with both ticagrelor and aspirin for 3 months after coronary intervention followed by ticagrelor only for a year rather than both aspirin and ticagrelor is better in reducing the ischemic events in high risk patients www.ctri.nic.in\/Clinicaltrials\/pdf_generate php?trialid=12839&EncHid=&modid=&compid=%27,%2712839det%27"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0621|cit621","unstructured":"Examination concerning utility and safety of cilostazol use in patients with PAD conplicated to CKD www.upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view cgi?recptno=R000003304"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD008834.pub4-BIB0622|cit622","first-page":"1092","article-title":"Pentoxifylline in diabetic kidney disease: the VA pentoxifylline in diabetic kidney disease PTXRX study [abstract no: PUB074]","volume":"30","author":"Leehey","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD008834.pub4-BIB0623|cit623","first-page":"775","article-title":"Design of pentoxifylline in diabetic kidney disease (VA PTXRx) [abstract no: SA-PO154]","volume":"29","author":"Leehey","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0624|cit624","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ndt\/14.3.648","article-title":"Cardiovascular morbidity and risk factors in renal transplant patients","volume":"14","author":"Aakhus","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0625|cit625","first-page":"S13","article-title":"Special characteristics of atherosclerosis in chronic renal failure","volume":"60 Suppl 1","author":"Amann","year":"2003","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0626|cit626","unstructured":"The 42nd Annual Report 2019 (Data to 2018) www.anzdata.org.au\/?s=annual+report&data-group=anzdata"},{"issue":"7329","key":"10.1002\/14651858.CD008834.pub4-BIB0627|cit627","first-page":"71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.[Erratum in: BMJ 2002 Jan 19;324(7330):141]","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"9678","key":"10.1002\/14651858.CD008834.pub4-BIB0628|cit628","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"7 Suppl 2","key":"10.1002\/14651858.CD008834.pub4-BIB0629|cit629","first-page":"S131","article-title":"Prevalence of kidney damage in Australian adults: The AusDiab kidney study","volume":"14","author":"Chadban","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0630|cit630","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0735-1097(03)00572-2","article-title":"Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction","volume":"42","author":"Berger","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0631|cit631","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0632|cit632","first-page":"48","article-title":"Use of defibrotide in renal transplantation in man","volume":"16 Suppl 1","author":"Bonomini","year":"1986","journal-title":"Haemostasis"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0633|cit633","unstructured":"Vascular access www.cariguidelines.org\/guidelines\/dialysis\/vascular-access\/"},{"issue":"9502","key":"10.1002\/14651858.CD008834.pub4-BIB0634|cit634","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD008834.pub4-BIB0635|cit635","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1742-1241.2009.02329.x","article-title":"Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis","volume":"64","author":"Coleman","year":"2010","journal-title":"International Journal of Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0636|cit636","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000441-200304000-00002","article-title":"Cardiovascular mortality in end-stage renal disease","volume":"325","author":"Collins","year":"2003","journal-title":"American Journal of the Medical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0637|cit637","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ccl.2005.04.002","article-title":"Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management","volume":"23","author":"Curtis","year":"2005","journal-title":"Cardiology Clinics"},{"issue":"16","key":"10.1002\/14651858.CD008834.pub4-BIB0638|cit638","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis","volume":"302","author":"Jager","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0639|cit639","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccl.2005.03.002","article-title":"Pathophysiology of cardiovascular disease and renal failure","volume":"23","author":"Dikow","year":"2005","journal-title":"Cardiology Clinics"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0640|cit640","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.HYP.0000142248.54761.56","article-title":"The burden of adult hypertension in the United States 1999 to 2000: a rising tide","volume":"44","author":"Fields","year":"2004","journal-title":"Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0641|cit641","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0642|cit642","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1523-1755.2005.09906.x","article-title":"Chronic renal failure: a cardiovascular risk factor","volume":"99","author":"Fort","year":"2005","journal-title":"Kidney International - Supplement"},{"issue":"13","key":"10.1002\/14651858.CD008834.pub4-BIB0643|cit643","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.[Erratum in: N Engl J Med. 2008;18(4):4]","volume":"351","author":"Go","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7650","key":"10.1002\/14651858.CD008834.pub4-BIB0644|cit644","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0645|cit645","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0646|cit646","unstructured":"GRADE Working Group Grading of Recommendations Assessment, Development and Evaluation (GRADE) www.gradeworkinggroup.org"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0647|cit647","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence--imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"18","key":"10.1002\/14651858.CD008834.pub4-BIB0648|cit648","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.118.033580","article-title":"Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease","volume":"139","author":"Gurbel","year":"2019","journal-title":"Circulation"},{"issue":"7414","key":"10.1002\/14651858.CD008834.pub4-BIB0649|cit649","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0650|cit650","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviewsof Interventions version 6.1 (updated September 2020) Cochrane, 2020. Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"12","key":"10.1002\/14651858.CD008834.pub4-BIB0651|cit651","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.kjms.2014.10.002","article-title":"Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease","volume":"30","author":"Hung","year":"2014","journal-title":"Kaohsiung Journal of Medical Science"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0652|cit652","first-page":"176","article-title":"Cardiovascular disease after renal transplantation","volume":"20","author":"Kasiske","year":"2000","journal-title":"Seminars in Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0653|cit653","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Seminars in Dialysis"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0654|cit654","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0655|cit655","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1212\/01.wnl.0000229099.62706.a3","article-title":"Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease","volume":"67","author":"Koren-Morag","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD008834.pub4-BIB0656|cit656","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0657|cit657","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mhj.2002.125513","article-title":"Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease","volume":"144","author":"McCullough","year":"2002","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0658|cit658","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.289.1.76","article-title":"Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001","volume":"289","author":"Mokdad","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0659|cit659","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.0894-0959.2004.17351.x","article-title":"Use of low molecular weight heparins and glycoprotein IIb\/IIIa inhibitors in patients with chronic kidney disease","volume":"17","author":"Mosenkis","year":"2004","journal-title":"Seminars in Dialysis"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0660|cit660","unstructured":"National Health and Nutrition Examination Survey www.cdc.gov\/nchs\/nhanes.htm"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0661|cit661","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial","volume":"48","author":"Norris","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD008834.pub4-BIB0662|cit662","first-page":"348","article-title":"Action mechanism and clinical indications for thrombocyte aggregation inhibitors","volume":"109","author":"Oelz","year":"1979","journal-title":"Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0663|cit663","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1523-1755.2000.00816.x","article-title":"Long-term survival in renal transplant recipients with graft function","volume":"57","author":"Ojo","year":"2000","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0664|cit664","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002786.pub2","article-title":"Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts","author":"Osborn","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0665|cit665","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1525-139X.2008.00457.x","article-title":"Cardiac problems in the dialysis patient: beyond coronary disease","volume":"21","author":"Remppis","year":"2008","journal-title":"Seminars in Dialysis"},{"issue":"8596","key":"10.1002\/14651858.CD008834.pub4-BIB0666|cit666","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(88)92019-3","article-title":"Bleeding in renal failure","volume":"1","author":"Remuzzi","year":"1988","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0667|cit667","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V122218","article-title":"Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study","volume":"12","author":"Ruilope","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0668|cit668","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0669|cit669","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1179\/acb.2008.63.2.003","article-title":"Medications in the kidney","volume":"63","author":"Scheen","year":"2008","journal-title":"Acta Clinica Belgica"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0670|cit670","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"Schr\u00f6r","year":"1997","journal-title":"Seminars in Thrombosis & Hemostasis"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0671|cit671","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0672|cit672","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org\/handbook"},{"issue":"7387","key":"10.1002\/14651858.CD008834.pub4-BIB0673|cit673","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0674|cit674","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0030-1267856","article-title":"Review of currently available GP IIb\/IIIa inhibitors and their role in peripheral vascular interventions","volume":"27","author":"Stangl","year":"2010","journal-title":"Seminars in Interventional Radiology"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0675|cit675","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12882-019-1499-3","article-title":"Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"20","author":"Su","year":"2019","journal-title":"BMC Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0676|cit676","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s10157-006-0433-8","article-title":"Meta-analysis of antiplatelet therapy for IgA nephropathy","volume":"10","author":"Taji","year":"2006","journal-title":"Clinical & Experimental Nephrology"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0677|cit677","unstructured":"UK Renal Association Cardiovascular disease in CKD www.renal.org\/Clinical\/GuidelinesSection\/CardiovascularDiseaseInCKD.aspx#Rationale3"},{"key":"10.1002\/14651858.CD008834.pub4-BIB0678|cit678","unstructured":"USRDS 2010 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD www.usrds.org\/annual-data-report\/previous-adrs\/"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0679|cit679","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008834.pub4-BIB0680|cit680","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"Weiner","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008834.pub4-BIB0681|cit681","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.ajkd.2004.04.024","article-title":"Kidney disease as a risk factor for recurrent cardiovascular disease and mortality","volume":"44","author":"Weiner","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008834.pub4-BIB0682|cit682","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ahj.2011.09.003","article-title":"Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study","volume":"162","author":"Woo","year":"2011","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD008834.pub4-BIB0683|cit683","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.ATV.11.3.733","article-title":"Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma","volume":"11","author":"Zwaginga","year":"1991","journal-title":"Arteriosclerosis & Thrombosis"},{"issue":"1","key":"10.1002\/14651858.CD008834.pub4-BIB0684|cit684","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2012.08.031","article-title":"Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis","volume":"61","author":"Palmer","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008834.pub4-BIB0685|cit685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008834.pub3","article-title":"Antiplatelet agents for chronic kidney disease","author":"Palmer","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008834.pub4-BIB0686|cit686","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008834","article-title":"Antiplatelet agents for chronic kidney disease","author":"Razavian","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:43:51Z","timestamp":1726749831000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008834.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":686,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008834.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}